Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484078 | 0.95 | KDM4E (0.45) | KDM4EL3MBTL1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4035649 | 0.88 | PPARA (0.49) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2SLC13A5 | |
| SCHEMBL3484594 | 0.87 | LMNA (0.48) | KDM4EL3MBTL1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4034269 | 0.84 | LTB4R (0.48) | KDM4EGAAALDH1A1 | |
| SCHEMBL3484528 | 0.82 | LTB4R (0.48) | KDM4EL3MBTL1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL3483937 | 0.82 | PPARA (0.46) | L3MBTL1 | |
| SCHEMBL3484666 | 0.78 | SLC13A5 (0.45) | SLC13A5 | |
| SCHEMBL11091256 | 0.74 | PPARA (0.46) | L3MBTL1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4033345 | 0.74 | PPARA (0.60) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL6950322 | 0.73 | KDM4E (0.46) | KDM4EALDH1A1KMT2ASLC13A5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | KDM4E 2600/4885L3MBTL1 4843/4885GAA 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.